Dr. David M. Meno, PharmD is the CEO/Founder of MAAM Radiopharmaceuticals, LLC. Receiving his BS in Biology and BS in Chemistry from Western Kentucky University, a Doctorate in Pharmacy from Mercer Southern School of Pharmacy graduating Cum Laude and obtained his Authorized User of radioactive materials certificate.
David excelled as a chemist for the state department of Florida in Tallahassee. Early in his career, David sat on the P&T committee for Vita-Link with over 350,000 lives in the Long-Term Care Community and also participated on advisory boards for Parke-Davis, TAP and Eli Lilly. David’s work in the underdiagnosed and untreated patients with depression and the health care cost impact of this disease was well received at his symposia at Harvard’s Faculty Club.
After spending time with Warner Lambert, Pfizer, and Astra Zeneca in roles to drive top lines sales of key promoted products and working with prover groups, David’s new challenge was to concentrate on his Nuclear Pharmacy training.
Starting up multiple radiopharmacies for Syncor, David’s roles as RSO and Pharmacy Manager got him to the point where he found himself working for an independent high-risk sterile compounding facility. Focusing his skills on USP 797, David quickly became lab/pharmacy manager in compounding products for lyophilization and radioactive preparations.
